Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Annovis Bio, Inc.NYSE: ANVS
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 87.0% from a year ago
Total equity stood at $3.13M at the end of Q1 FY2026, down 87.0% from a year earlier and down 81.4% from the prior quarter. Over 3 fiscal years it compounded at -15.9% a year.
Context
- Total equity amounted to 19.2% of total assets at the end of Q1 FY2026, down 70.7 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -87.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 16.85M USD
- Year-over-year change
- +81.0%
- 4-year CAGR
- -21.6%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.85M | +81.0% |
| FY2024 | 2024-12-31 | 9.31M | +220.1% |
| FY2023 | 2023-12-31 | (7.75M) | -127.4% |
| FY2022 | 2022-12-31 | 28.32M | -36.3% |
| FY2021 | 2021-12-31 | 44.49M | — |
Total Equity vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 total equity of $3.13M is the 5th highest of the 6 companies compared; the peer median is $8.78M.
- Its year-over-year change of -87.0% is the 5th highest of 6, against a peer median of +59.4%.
- Total equity amounts to 19.2% of total assets for ANVS, versus a peer median of 45.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $30.3M | +59.4% | -51.0% | 75.5% | |
| Mar 2026 | $27.76M | +461.7% | -34.6% | 78.6% | |
| Mar 2026 | $8.78M | +10109.3% | +23.5% | 45.8% | |
| Mar 2026 | $3.89M | -82.6% | -40.5% | 15.8% | |
| Mar 2026 | $3.13M | -87.0% | -15.9% | 19.2% | |
| Dec 2025 | -$38.06M | -530.7% | — | 35.5% | |
| Peer median (excluding ANVS) | $8.78M | +59.4% | -37.6% | 45.8% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.